

Monthly statement of total voting rights and shares forming the company's share capital

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

Market: Euronext Paris
 ISIN code / Mnemo: CH0308403085 / GNRO
 Web site: www.geneuro.com

Date	Number of shares outstanding ⁽¹⁾	Total voting rights, gross ⁽²⁾	Total voting rights, net ⁽³⁾
January 31, 2020	14,658,118	14,658,118	14,543,972
February 29, 2020	20,590,319	20,590,319	20,476,463
March 31, 2020	20,590,319	20,590,319	20,477,516
April 30, 2020	20,590,319	20,590,319	20,472,555
May 31, 2020	20,590,319	20,590,319	20,471,378
June 30, 2020	20,590,319	20,590,319	20,479,938
July 31, 2020	20,590,319	20,590,319	20,475,396
August 31, 2020	20,590,319	20,590,319	20,477,353
September 30, 2020	20,590,319	20,590,319	20,475,650
October 31, 2020	20,590,319	20,590,319	20,470,901
November 30, 2020	20,590,319	20,590,319	20,450,710
December 31, 2020	20,590,319	20,590,319	20,450,674

(1) reflecting the capital increase of January 31, 2020, with settlement on February 4, 2020

(2) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

(3) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It owns rights to 17 patent families protecting its technology.

For more information, visit: www.geneuro.com

Contacts

GeNeuro

Miguel Payró
 CFO
 +41 22 552 48 00
investors@geneuro.com

NewCap (France)

Mathilde Bohin (investors)
 +33 1 44 71 98 52
 Nicolas Merigeau (media)
 +33 1 44 71 94 98
geneuro@newcap.eu

Halsin Partners

Mike Sinclair (media)
 +44 20 7318 2955
msinclair@halsin.com

LifeSci Advisors

Chris Maggos (investors)
 +41 79 367 6254
chris@lifesciadvisors.com